Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
Satoshi Watanabe(Niigata University Medical and Dental Hospital), Kunihiko Kobayashi(Saitama International Medical Center), Koichi Hagiwara(Jichi Medical University), Akihiko Gemma(Nippon Medical School), Hiroshi Isobe, Akira Inoue(Tohoku University Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Yoshiki Ishii(Dokkyo Medical University), Yuji Minegishi, Hirohisa Yoshizawa(Niigata University Medical and Dental Hospital), Masao Harada(Shikoku Cancer Center), Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 204
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695